Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Apellis Pharmaceuticals (Nasdaq: APLS) announced management will participate in webcast fireside chats at two investor conferences: Citi 2025 Global Healthcare Conference on December 2, 2025 at 2:30 p.m. ET and Evercore 8th Annual Healthcare Conference on December 3, 2025 at 2:10 p.m. ET.
Live webcasts will be posted on the company’s Investors and Media > Events and Presentations webpage. A replay will be available for approximately 30 days after each event.
Details
News Market Reaction – APLS
On Nov 25, the day this news came out, APLS closed 4.32% above the previous close.
Data tracked by StockTitan Argus for the Nov 25 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that management will participate in webcast fireside chats at the following investor conferences:
Citi’s 2025 Global Healthcare Conference
Date/Time: Tuesday, December 2, 2025 at 2:30 p.m. ET
Evercore 8th Annual Healthcare Conference
Date/Time: Wednesday, December 3, 2025 at 2:10 p.m. ET
The live conference webcasts will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcasts will be available for approximately 30 days following the event.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3-targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first-ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC-MPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on LinkedIn and X.
Investor Contact:
Eva Stroynowski
ir@apellis.com
617.938.6229
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.